Clinical Data Lilly’s ‘triple G’ retatrutide aces crucial obesity trial PharmaphorumLilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.Metabolic & GLP-1Read full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaphorum Lilly’s retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug. Metabolic & GLP-1 Read full story Post navigation Previous: Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rollingNext: Lilly’s triple agonist shows bariatric surgery-like weight loss results Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
